Stock listing
Frankfurt:1RT Nuformix PLC Aktie
German listing (Frankfurt) of Nuformix PLC · home listing LSE:NFX
Follow Nuformix PLC into a list and get an email when it puts out news.
Share price · FWB:1RT
€0.0010 EUR 0.0000 (0.0%)
Close on Nov 20, 2026
- Day range
- €0.0010 – €0.0010 EURNov 20, 2026
- Market cap
- €2.61M EURAt the close on Nov 20, 2026 · price × 2.61B shares outstanding
- 52-week range
- €0.0010 – €0.0020 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €9 EURMedian day 0 shares · 56 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:NFX · Home | 0.065p GBX (pence) | 0.000 (0.0%) | 49,893,992 | 0.065p | 0.067p | 0.053p | 0.065p | Close on Nov 20, 2026 |
| Frankfurt:1RT | €0.0010 EUR | 0.0000 (0.0%) | — | €0.0010 | €0.0010 | €0.0010 | €0.0010 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:1RT · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 500,000 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | 0.0000 | 0.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0010 | -0.0010 | -50.0% | €0.0010 | €0.0010 | €0.0010 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 | |
| €0.0020 | 0.0000 | 0.0% | €0.0020 | €0.0020 | €0.0020 | 0 |
- Ticker
- Frankfurt:1RT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 11, 2026
Proposed Acquisition of Biovara
Latest news
NXP002 Development Update
Oct 19, 2026
Closed €0.0010 (0.0%) on Oct 19, 2026
Appointment of Chairman
Aug 25, 2026
Closed €0.0020 (0.0%) on Aug 25, 2026
Half Year Report
May 28, 2026
Closed €0.0010 (0.0%) on May 28, 2026
Total Voting Rights
Mar 31, 2026
Closed €0.0010 (0.0%) on Apr 1, 2026
£1.0 million Placing
Mar 11, 2026
Closed €0.0010 (0.0%) on Mar 11, 2026
Confirmation of US ODD for NXP002 in IPF
Mar 10, 2026
Closed €0.0010 (0.0%) on Mar 10, 2026
Result of AGM
Mar 3, 2026
Closed €0.0010 (0.0%) on Mar 3, 2026
Posting of Annual Report and Notice of AGM
Feb 5, 2026
Closed €0.0010 (0.0%) on Feb 5, 2026
Annual Results for period ended 30 September 2025
Jan 27, 2026
Closed €0.0010 (0.0%) on Jan 27, 2026
Nuformix PLC on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 11 in the last 12 months · 138 in all · newest Nov 11, 2026 · oldest 2015
- Decks
- 3 decks · latest Nov 9, 2022
Where Nuformix PLC is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:NFX · Home listing | LSE | United Kingdom | GBX |
| Lang & Schwarz:A141LG | Lang & Schwarz | Germany | EUR |
| LS Exchange:A141LG | LS Exchange | Germany | EUR |
| Frankfurt:1RT · This page | Frankfurt | Germany | EUR |
| Stuttgart:1RT | Stuttgart | Germany | EUR |
Valuation
Price/book 1.0× against a median of 0.3×: 7th lowest of 8 Biotechnology companies shown. Statements: Year to Sep 30, 2025 · balance Mar 31, 2026 · price Nov 20, 2026
- Enterprise value
- £766,054 GBP
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nuformix PLC · LSE:NFX | US$2.22M | US$1.00M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Cynata Therapeutics Limited · ASX:CYP | US$2.26M | US$1.66M | n/a | 1.5× | n/a | n/a | −540.4% | n/a | n/a |
| PharmaCyte Biotech, Inc. · NASDAQ:PMCB | US$2.25M | −US$15.59M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 1.97 |
| Modus Therapeutics Holding AB · OMXSTO:MODTX | US$2.22M | US$1.00M | n/a | n/a | n/a | 2.2× | n/a | 0.0× | n/a |
| Medicus Pharma Ltd. · NASDAQ:MDCX | US$2.18M | −US$2.73M | n/a | n/a | n/a | n/a | n/a | n/a | 2.03 |
| Senti Biosciences Holdings, Inc. · NASDAQ:SNTI | US$2.06M | −US$3.49M | n/a | −47.2× | n/a | n/a | n/a | n/a | 2.91 |
| Median of the others | US$2.28M | −US$2.85M | 0.7× | 1.2× | 0.3× | −301.9% | 0.0× | 1.78 |
Team and board
Officers
| Officer | Role |
|---|---|
| Dan Gooding | Executive Director |
Board
| Director | Role |
|---|---|
| Tim Metcalfe | Non-Executive Chairman |
| Dan Gooding | Executive Director |
| Maddy Kennedy | Non-Executive Director |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2022) | Investor deck | 26 slides | Nov 9, 2022 |
| Investor Presentation (April 2021) | Investor deck | 23 slides | April 2021 |
| Investor Presentation (April 2021) | Investor deck | 23 slides | April 2021 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of open Offer Shares (ordinary shares) Announced: about £228,081 · GBX 0.2 a share · CMC Markets UK Plc Dealers: CMC Markets UK Plc Use of proceeds: Assess NXP002's inhaled therapeutic window, support partnering and out-licensing talks, maintain key IP, and working capital | Oct 28, 2025 | US$302,850 |
| Private placement of new ordinary shares Update: £210,000 · GBX 0.07 a share · CMC Markets UK Plc Dealers: CMC Markets UK Plc | May 23, 2025 | US$283,766 |
| Warrant exercise of new ordinary shares Announced: £13,200 · GBX 0.05 a share | Apr 14, 2025 | US$17,392 |
| Private placement of new ordinary shares Announced: £168,750 · GBX 0.0675 a share · CMC Markets UK Plc, trading as CMC CapX Dealers: CMC Markets UK Plc, trading as CMC CapX (lead) Use of proceeds: Progress partnering discussions for NXP002 inhaled IPF/PPF programme and general corporate purposes | Jan 30, 2025 | US$210,182 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 50.0K | 195.6K | 535.0K | 610.0K | 15.0K | 0 | |
| Cost of revenue | 28.6K | 29.2K | 36.7K | 0 | 38.7K | 108.8K | 333.6K | 537.5K | 203.9K | 86.2K |
| Gross profit | -28.6K | -29.2K | -36.7K | 0 | 11.3K | 86.7K | 201.4K | 72.5K | -188.9K | -86.2K |
| Research and development | 95.3K | 70.9K | 163.4K | 572.9K | 362.9K | 525.0K | 1.45M | 876.6K | 472.0K | |
| Selling, general and administrative | 660.6K | 506.4K | 618.6K | 761.3K | 1.32K | 1.51K | 1.12K | 911.7K | 729.0K | 685.1K |
| Operating income | -660.6K | -3.65M | -618.6K | -761.3K | -1.27M | -1.37M | -918.2K | -1.81M | -1.96M | -685.1K |
| Depreciation and amortization | 28.6K | 29.2K | 36.7K | 36.9K | 37.0K | 93.1K | 81.7K | 52.8K | 47.4K | 35.0K |
| EBITDA | -631.9K | -3.62M | -581.9K | -724.4K | -1.23M | -1.28M | -836.5K | -1.76M | -1.91M | -650.0K |
| Interest expense | 0 | 0 | 3.05K | 15.3K | 28.4K | 11.1K | 1.76K | |||
| Income before tax | -660.6K | -3.65M | -618.6K | -761.3K | -1.27M | -1.38M | -929.9K | -1.84M | -1.97M | -685.1K |
| Income tax | -7.98K | -5.57K | -45.7K | -1.16K | -161.3K | -122.2K | -173.5K | -181.5K | -126.8K | -68.4K |
| Net income | -652.6K | -3.64M | -573.0K | -760.1K | -1.11M | -1.25M | -756.4K | -1.66M | -1.84M | -685.1K |
| Earnings per share, basic | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 97.5K | 20.2K | 202.5K | 259.3K | 464.1K | 1.67M | 543.8K | 4.26K | 338.2K | 5.89K |
| Receivables | 16.1K | 15.8K | 116.3K | 128.5K | 332.9K | 138.5K | 207.2K | 327.7K | 350.0K | 83.2K |
| Inventory | -116.3K | -332.9K | 0 | -83.2K | ||||||
| Current assets | 136.1K | 59.1K | 336.7K | 387.8K | 825.0K | 1.82M | 795.7K | 347.0K | 713.7K | 19.6K |
| Property, plant and equipment | 438 | 957 | 82.9K | 27.5K | 37.5K | 1.73K | ||||
| Goodwill | 882.8K | 882.8K | 4.02M | 4.02M | 4.02M | 4.02M | 4.02M | 4.02M | 4.02M | |
| Total assets | 1.02M | 970.5K | 4.42M | 4.50M | 4.98M | 6.01M | 5.13M | 4.63M | 5.03M | 19.6K |
| Accounts payable | 46.3K | 32.9K | 69.8K | 273.6K | 12.4K | 99.0K | 131.0K | 322.1K | 89.6K | 163.4K |
| Current liabilities | 263.9K | 255.0K | 223.0K | 273.6K | 237.9K | 324.6K | 346.7K | 819.5K | 534.0K | 199.2K |
| Total debt | 75.4K | 15.1K | 23.0K | 187.9K | ||||||
| Total liabilities | 263.9K | 255.0K | 223.0K | 273.6K | 237.9K | 324.6K | 383.9K | 819.5K | 534.0K | 199.2K |
| Shareholders' equity | 754.9K | 715.6K | 4.20M | 4.23M | 4.74M | 5.69M | 4.74M | 3.82M | 4.49M | -179.6K |
| Shares outstanding | 1.66B | 786.9M | 719.5M | 598.4M | 598.4M | 580.6M | 477.1M | 460.8M | 373.5M | 95.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -614.6K | -331.9K | -546.2K | -433.1K | -1.35M | -848.2K | -727.6K | -299.3K | -1.53M | -496.3K |
| Capital spending | 0 | 0 | -2 | 0 | 0 | -605 | -43.2K | -1.28K | -44.1K | -93.3K |
| Free cash flow | -614.6K | -331.9K | -397.5K | -433.1K | -1.35M | -848.8K | -770.8K | -300.6K | -1.58M | -589.6K |
| Cash from investing | 33.3K | 43.7K | -43.2K | -27.3K | -100.6K | -93.3K | ||||
| Cash from financing | 692.0K | 149.5K | 189.8K | 228.3K | 140.0K | 1.93M | 1.31M | -7.29K | 1.97M | -19.6K |
| Change in cash | 77.3K | -182.3K | -204.8K | -204.8K | -1.21M | 1.13M | 539.5K | -333.9K | 333.7K | -496.3K |
Cap table
Built by 6ix from Nuformix PLC’s releases · as of Oct 28, 2025
- Common shares
- 2,609,749,368
- Fully diluted
- 2,609,749,368
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,609,749,368 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,609,749,368 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Dan Gooding | Executive Director · Since at least Oct 19, 2026 |
| Maddy Kennedy | Non-Executive Director · Since at least Nov 5, 2024 |
| Tim Metcalfe | Non-Executive Chairman · Since at least Oct 19, 2026 |
Log in to ask 6ix AI your own questions about Nuformix PLC.